- Home
- VRE vs GPCR Comparison
VRE vs GPCR Comparison
Compare VRE & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRE
- GPCR
- Stock Information
- Founded
- VRE 1949
- GPCR 2016
- Country
- VRE United States
- GPCR United States
- Employees
- VRE N/A
- GPCR N/A
- Industry
- VRE Real Estate Investment Trusts
- GPCR
- Sector
- VRE Real Estate
- GPCR
- Exchange
- VRE Nasdaq
- GPCR Nasdaq
- Market Cap
- VRE 1.6B
- GPCR 1.8B
- IPO Year
- VRE 1994
- GPCR 2023
- Fundamental
- Price
- VRE $17.39
- GPCR $39.62
- Analyst Decision
- VRE Hold
- GPCR Buy
- Analyst Count
- VRE 3
- GPCR 6
- Target Price
- VRE $15.67
- GPCR $87.83
- AVG Volume (30 Days)
- VRE 389.4K
- GPCR 759.0K
- Earning Date
- VRE 10-30-2024
- GPCR 11-12-2024
- Dividend Yield
- VRE 1.61%
- GPCR N/A
- EPS Growth
- VRE N/A
- GPCR N/A
- EPS
- VRE N/A
- GPCR N/A
- Revenue
- VRE $292,145,000.00
- GPCR N/A
- Revenue This Year
- VRE N/A
- GPCR N/A
- Revenue Next Year
- VRE $4.67
- GPCR N/A
- P/E Ratio
- VRE N/A
- GPCR N/A
- Revenue Growth
- VRE 12.90
- GPCR N/A
- 52 Week Low
- VRE $13.07
- GPCR $26.61
- 52 Week High
- VRE $18.18
- GPCR $75.02
- Technical
- Relative Strength Index (RSI)
- VRE 49.14
- GPCR 49.48
- Support Level
- VRE $17.15
- GPCR $34.83
- Resistance Level
- VRE $17.70
- GPCR $43.46
- Average True Range (ATR)
- VRE 0.26
- GPCR 2.36
- MACD
- VRE -0.04
- GPCR -0.45
- Stochastic Oscillator
- VRE 46.07
- GPCR 48.43
About VRE Veris Residential Inc.
Veris Residential Inc is a fully-integrated, self-administered and self-managed real estate investment trust (REIT). The company owns and operates a real estate portfolio comprised predominantly of multifamily rental properties located mainly in the Northeast and Class A office properties. The company performs substantially all real estate management, leasing, acquisition and development on an in-house basis. The properties are in three states in the Northeast, plus the District of Columbia. The company operates in two industry segments multifamily real estate & services and commercial & other real estate. The majority of revenue is from Multifamily real estate services.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company aiming to develop and deliver novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small-molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073 and LTSE-2578.